X
Exelixis’ Cabometyx approved in second-line liver cancer in US
https://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/
Exelixis
Ipsen/Exelixis’ drug approved in EU for kidney cancer
Cabometyx secures new indication in renal cell carcinoma.